KUALA LUMPUR, March 29 (Bernama) -- Crown Bioscience has been chosen by Glycotope GmbH as a partner to accelerate their immuno-oncology drug discovery pipeline.
Crown Bioscience said it will engraft cell line-derived cancer models as well as PDX models selected by Glycotope into CD34+ humanised mouse models.
"These customised, humanised models will be used to accelerate Glycotope´s innovative immuno-oncology drug discovery pipeline, " a statement said.
Director of Glycotope´s Preclinical Pharmacology and Cancer Immunology group, Anika J?l said the company recognised the value of CrownBio´s extensive PDX and CDX collection and their expertise in implementing innovative humanisation strategies.
"We have chosen them as our partner for these reasons and look forward to what we are confident will be a successful alliance, " she added.
Chief business officer of Crown Bioscience, Laurie Heilmann, meanwhile said its unique capabilities would enable Glycotope to continue providing new and improved therapies for the treatment of cancer.
Crown Bioscience is a global drug discovery and development solutions company, providing translational platforms to advance oncology, inflammation, cardiovascular and metabolic disease research.
Glycotope GmbH is a company focuses on development of innovative immuno-oncological products for the treatment of various cancer types.
--BERNAMA
No comments:
Post a Comment